Chloroquine News and Research

RSS

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

COVID-19 researchers review 184 drug repurposing candidates

New research describes the use of integrative bioinformatics analyses of transcriptomic profiles for COVID-19 therapeutics.

15 Jul 2021

Is niclosamide a potential SARS-CoV-2 antiviral inhibitor?

Niclosamide is an antihelminthic drug, historically used to treat tapeworm infestations, though has been investigated and repurposed for use against SARS-CoV-2. In a new study recently uploaded to the preprint server bioRxiv* by Garrett et al. (July 12, 2021), the drug demonstrates the ability to reorganize the lipid profile of SARS-CoV-2 infected Vero E6 cells, thereby limiting virus replication.

14 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

A team of researchers recently optimized regimens for CVac, wherein aseptic, purified, cryopreserved, and infectious PfSPZ were inoculated and mixed with PYR and CQ.

5 Jul 2021

New malaria vaccine is undergoing Phase 1 trials but current results show it provides strong and long-lasting protection

A new malaria vaccine could be the breakthrough in developing an effective and lasting treatment.

1 Jul 2021

Novel candidate malaria vaccine confers high levels of durable protection

Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites.

30 Jun 2021

Sanaria researchers make progress in the development of highly protective malaria vaccine

Researchers from Sanaria Inc. and the National Institutes of Health are making progress in the development of highly protective malaria vaccines.

30 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Study explores therapeutic potential of exploiting autophagy cascade against COVID-19

Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.

7 Jun 2021

How can nanomaterials help in the fight against COVID-19?

Researchers have reviewed different types of nanomaterials and how they can be used for the detection, prevention, and treatment of coronavirus disease 2019 (COVID-19).

3 Jun 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

World Malaria Day 2021: An interview with Sir Brian Greenwood

News-Medical interviews Sir Brian Greenwood about raising awareness for malaria during the COVID-19 pandemic and achieving elimination of the disease.

23 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Malaria mutations may be gaining a foothold in Africa, shows new data

New data provide the first clinical evidence that drug-resistant mutations in the malaria parasite Plasmodium falciparum may be gaining a foothold in Africa.

15 Apr 2021

Administering zinc supplements to Covid-19 patients may help reduce mortality and recovery time

Administering zinc supplements to Covid-19 patients with low levels of this element may be a strategy to reduce mortality and recovery time.

4 Mar 2021

Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells

The clinical phenotype of COVID-19, caused by SARS-CoV-2, is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences. To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donor’s genetic information. Researchers use a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.

25 Feb 2021

New Cochrane Review: Hydroxychloroquine does not reduce deaths from COVID-19

Hydroxychloroquine does not reduce deaths from COVID-19, and probably does not reduce the number of people needing mechanical ventilation, state the authors of a new Cochrane Review.

13 Feb 2021